

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4854435

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	QUANTICEL PHARMACEUTICALS, INC.	02/26/2018
RECEIVING PARTY DATA		
Name:	CELGENE QUANTICEL RESEARCH, INC	
Street Address:	9393 TOWNE CENTRE DRIVE	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92121	
PROPERTY NUMBERS Total: 4		
Property Type	Number	
Application Number:	62413763	
Application Number:	62560840	
Application Number:	15796571	
PCT Number:	US2017058614	
CORRESPONDENCE DATA		
Fax Number:	(202)719-7049	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	ptodocket@wileyrein.com, xsu@wileyrein.com	
Correspondent Name:	WILEY REIN LLP	
Address Line 1:	1776 K STREET NW	
Address Line 4:	WASHINGTON DC, D.C. 20006	
ATTORNEY DOCKET NUMBER:	87386.0003\US	
NAME OF SUBMITTER:	XIAOMIN SU	
SIGNATURE:	/xiaomin su/	
DATE SIGNED:	03/07/2018	
Total Attachments: 4		
source=87386_0003_Assignment_Quantice Celgene#page1.tif		
source=87386_0003_Assignment_Quantice Celgene#page2.tif		
source=87386_0003_Assignment_Quantice Celgene#page3.tif		
source=87386_0003_Assignment_Quantice Celgene#page4.tif		

ASSIGNMENT

WHEREAS I/WE,

QUANTICEL PHARMACEUTICALS, INC.

9393 Towne Centre Drive
San Diego, CA 92121
United States of America

respectively ("Assignor"), have made a certain new and useful invention as set forth in the U.S. and International Patent Application Numbers in the attached Exhibit A.

AND WHEREAS,

CELGENE QUANTICEL RESEARCH, INC.

9393 Towne Centre Drive
San Diego, CA 92121
United States of America

respectively ("Assignee"), is desirous of acquiring the entire right, title and interest in and to said invention and application, and in and to any and all Letters Patent of any country which may be obtained therefore;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer and set over unto Assignee, its legal representatives, successors, and assigns, the entire right, title and interest in and to said invention and application, including the right to claim priority under 35 U.S.C. §119 and/or §120 the right to sue for past infringement, as set forth in the above-mentioned application, including any continuations, continuations-in-part, divisions, reissues, re-examinations or extensions thereof, and in and to any and all patents of any country which may be issued for said invention;

UPON SAID CONSIDERATION, Assignor hereby agrees with the said Assignee that Assignor will not execute any writing or do any act whatsoever conflicting with these presents, and that Assignor will, at any time upon request, without further or additional consideration but at the expense of said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining original, divisional, continuations, continuations-in-part, reexamined, reissued, or extended Letters Patent of any country on said invention, and in enforcing any rights or chooses in action accruing as a result of such applications or patents, by giving testimony in any proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of the assigns and legal representatives of Assignor and Assignee;

PATENT

REEL: 045128 FRAME: 0800

The undersigned hereby grant(s) the firm of WILEY REIN LLP the power to insert on this Assignment any further identification, including the application number and filing date, which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


This Assignment may be executed in counterparts and all such counterparts shall constitute one and the same instrument.

AND Assignor requests the Commissioner of Patents and Trademarks to issue any Letters Patent of the United States which may be issued for said invention to said Assignee, its legal representatives, successors or assigns, as the sole owner of the entire right, title and interest in and to said patent and the invention covered thereby.

In witness thereof, this Assignment has been executed by the undersigned on the date(s) opposite the undersigned name(s).

February 26, 2018
Date

QUANTICEL PHARMACEUTICALS, INC.
CELGENE QUANTICEL RESEARCH, INC.



86 Morris Ave., Summit, NJ 07901 - USA

Peter Cicola
Vice President, Intellectual Property

This assignment should preferably be acknowledged before a United States Consul or Notary Public. If not, then the execution by the representative should be witnessed by at least two other persons who should sign here.

Witness_____

Signature_____

Witness_____

Signature_____

Witness_____

Signature_____

EXHIBIT A

ASSIGNMENT LISTING OF U.S. AND PCT APPLICATIONS

Docket No.	Application No.	Filing Date
87386.0003\PRO	62/413,763	10/27/2016
87386.0003\PR1	62/560,840	9/20/2017
87386.0003\US	15/796,571	10/27/2017
87386.0003\PCT	PCT/US2017/058614	10/26/2017

On February 26, 2018 before me, Maureen Manson, Notary Public in and for said county, personally appeared Peter Cicala, (signer/witness) who has/have satisfactorily identified him/her/themselves as the signer(s) or witness(es) to the above referenced document.

(Affix Notary Stamp Here)

Maureen Monce
Notary Public Signature

My Commission Expires:

